mRNA-1273 is being developed by U.S.-based Moderna Inc. (MRNA) and the National Institute of Allergy and Infectious Diseases (NIAID).Current Status: mRNA-1273 is under phase II testing in the U.S.Mode of Action: The mRNA-1273 vaccine contains an mRNA or the genetic formula that encodes for a prefusion stabilized form of the SARS-CoV-2 spike protein. Upon vaccination, the body cells will start producing the spike protein, triggering the production of antigens to act against the virus, thus eliciting immunity.Next Milestones: Initiation of phase III study of mRNA-1273 COVID-19 vaccine in July 2020.